Effects of prednisolone in chronic airflow limitation.

摘要: Abstract A double-blind, randomised, placebo-controlled, crossover trial of prednisolone (40 mg daily for 14 days) was carried out in 43 patients with chronic airflow limitation (mean age 60 years, mean FEV 1 1·02 litres, /FVC ratio 43·7%). Several subjective and objective variables response were measured. Significant improvements occurred most measured, but also placebo some variables. The general wellbeing, 12 min walk distance, peak expiratory flow, , relaxed vital capacity significantly greater than those placebo. Clinical assessment atopic status did not reveal any feature major predictive value steroid responsiveness. proportion do improve on oral corticosteroids the continued use such trials clinical practice is justified, though a period should be included, several